Loading
CEL SCI Corp Stock: price and insider trades · United States
1 insider bought €118k of shares over the last 90 days, the latest filed 26 Aug 2026.
CEL SCI Corp: what insiders have been doing
Every trade that managers of CEL SCI Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Vienna, United States. It was founded in 1983. In the past year (18 October 2025 to 18 October 2026), 16 filings came from 3 insiders.
Every open-market trade in the period is a purchase: 4 purchases worth €434k, from 1 insider, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 chief executive. Biggest ticket of the year: €171k, bought by Kersten Geert R and made public on 26 January 2026.
The last insider purchase was made public on 26 August 2026, 52 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4.
Across the 5,814 companies tracked on its exchange, the median is 19 filings; at 16 filings, this issuer sits below that mark. The full history, which starts in 2016, counts 13 purchases against 1 sale.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
91
Thresholds
n/a
Buy Volume
€914,062
13 ops. · all time
Sell Volume
€145,074
1 ops. · all time
Who traded when
BuySaleGeert R. Kersten5 buys
Robert Eugene Watson1 buy
Since the insiders bought
- +8.7%Entry US$1.60 · Close 15 Oct 2026 US$1.74
- -85.8%Entry US$8.58 · Close at T+365 US$1.22
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended September 2025 · cache
US$1.71
Analyst consensus
2 analysts1.50/5
US$10.00Target US$12.50(+631%)US$15.00
Income statement
EBITDA-US$20.9M
Net income-US$25.4M0.0% margin
Valuation
PER (forward)-0.3x
P/Book2.7x
Beta0.59
Balance sheet & cash
Market capUS$30.1M
Total debtUS$9.4M
Free Cash Flow-US$17.2M
Debt / Equity72%
Profitability & ownership
ROE-252.5%
ROA-66.8%
% insiders3.7%
% institutions14.6%
Last declaration on 1 October 2026
Declarations91 total
1,165 shares@ US$2.060.0080% mcap100.0% of flowCommon StockSEC:0001238028-26-000005:0
2,082 shares@ US$2.060.014% mcap100.0% of flowCommon StockSEC:0001236215-26-000005:0
2,621 shares@ US$2.060.018% mcap3.9% of flowCommon StockSEC:0001236030-26-000009:0
100,000 shares@ US$1.380.46% mcap100.0% of flowCommon StockSEC:0001236030-26-000008:0
Canonical exit: 23 Nov 2026 (T+90)
5,192 sharesCommon StockSEC:0001236030-26-000006:0
4,125 sharesCommon StockSEC:0001236215-26-000003:0
2,307 sharesCommon StockSEC:0001238028-26-000003:0
100,000 shares@ US$1.190.44% mcap13.0% of flowCommon StockSEC:0001236030-26-000004:0
Canonical exit: 11 Aug 2026 (T+90)
1,336 shares@ US$3.214.3% of flowCommon StockSEC:0001236215-26-000002:0
747 shares@ US$3.211.1% of flowCommon StockSEC:0001238028-26-000002:0
1,682 shares@ US$3.210.6% of flowCommon StockSEC:0001236030-26-000003:0
38,023 shares@ US$5.2621.9% of flowCommon StockSEC:0001236030-26-000002:0
Canonical exit: 22 Apr 2026 (T+90)
998 shares@ US$5.260.6% of flowCommon StockSEC:0001236030-26-000001:0
456 shares@ US$5.261.1% of flowCommon StockSEC:0001238028-26-000001:0
815 shares@ US$5.264.2% of flowCommon StockSEC:0001236215-26-000001:0
8,389 shares@ US$5.965.5% of flowCommon StockSEC:0001236030-25-000019:0
Canonical exit: 4 Mar 2026 (T+90)
260 shares@ US$9.201.1% of flowCommon StockSEC:0001238028-25-000002:0
466 shares@ US$9.204.2% of flowCommon StockSEC:0001236215-25-000005:0
570 shares@ US$9.200.6% of flowCommon StockSEC:0001236030-25-000016:0
2,919 shares@ US$6.8533.1% of flowCommon StockSEC:0001236030-25-000008:0
Canonical exit: 23 Oct 2025 (T+90)
29,197 shares@ US$6.8521.8% of flowCommon StockSEC:0001236030-25-000007:0
Canonical exit: 23 Oct 2025 (T+90)
1,048 shares@ US$2.291.1% of flowCommon StockSEC:0001236030-25-000006:0
1,873 shares@ US$2.294.2% of flowCommon StockSEC:0001236030-25-000005:0
2,292 shares@ US$2.290.6% of flowCommon StockSEC:0001236030-25-000004:0
15,432 shares@ US$0.23043.8% of flowCommon StockSEC:0001236030-25-000002:0
25 of 91 declarations
About CEL SCI Corp
CEL-SCI Corp. (ticker: CVM) is a U.S.-listed biotechnology company traded on NYSE American, making it a small-cap healthcare name with high clinical and financing risk. The company was incorporated in 1983 in Colorado and is now headquartered in Vienna, Virginia, United States. Its business model is centered on research and development rather than commercial operations, with an almost singular focus on cancer immunotherapy.
CEL-SCI’s lead program is Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy being developed primarily for advanced, previously untreated head and neck cancer. According to the latest SEC filings, Multikine is intended to be administered locally at the tumor site soon after diagnosis and before surgery or radiation, with the goal of stimulating an anti-tumor immune response while the immune system is still intact. The company also describes a manufacturing footprint near Baltimore, Maryland, that has been developed in anticipation of potential commercialization.
Read moreShow less
From a competitive standpoint, CEL-SCI occupies a narrow niche. It does not yet have a diversified commercial portfolio or meaningful recurring product revenue, so the equity story is driven mainly by clinical progress, regulatory milestones, and access to capital. In oncology immunotherapy, competition is intense, with large pharmaceutical companies and numerous biotech peers pursuing alternative mechanisms and combinations. CEL-SCI’s differentiation lies in Multikine’s distinct treatment timing and cytokine-based design, but the execution risk remains substantial.
Recent company developments include continued work on the Multikine program, ongoing regulatory and partnering activity outside the United States, and an August 2025 Breakthrough Medicine Designation application submitted to the Saudi Food and Drug Authority for Multikine in Saudi Arabia through Dallah Pharma. Recent SEC disclosures also emphasize that CEL-SCI remains a late clinical-stage company with no approved products and continued dependence on external financing. For investors in French-speaking markets, CVM is therefore best viewed as a highly speculative biotech single-asset story: potentially meaningful upside if the program advances, but also elevated dilution risk and high sensitivity to clinical and regulatory news.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
